LISATA THERAPEUTICS, INC. Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2012-01-31)
LISATA THERAPEUTICS, INC. (LSTA) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2012-01-31) of $6.01 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-11.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax · last filed 2013-03-11
- LISATA THERAPEUTICS, INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2012-01-31) for fiscal 2012 was $6.01M.
- LISATA THERAPEUTICS, INC. other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, tax (deprecated 2012-01-31) for fiscal 2011 was $0.00.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Tax (Deprecated 2012-01-31) 12 month |
|---|---|
| 2012-12-31 | $6.01M 10-K · filed 2013-03-11 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |